{"filing":{"accession_number":"0001193125-26-257430","cik":"0001880438","ticker":"ANTX","company_name":"AN2 Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"d247428d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526257430/d247428d8k.htm"},"events":[{"id":6814,"run_id":5971,"accession_number":"0001193125-26-257430","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"AN2 Therapeutics announced positive clinical trial results for AN2-502998, an oral CPSF3 inhibitor for chronic Chagas disease, including 100% parasite elimination in a 28-day NHP study with no adverse events and Phase 1 FIH data demonstrating good tolerability and human exposures meeting efficacy thresholds. For a clinical-stage biopharmaceutical company, these results are material to investors' assessment of pipeline value and development progress.","company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4343,"accession_number":"0001193125-26-257430","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"AN2 Therapeutics announced positive clinical trial results for AN2-502998, an oral CPSF3 inhibitor for chronic Chagas disease. For a clinical-stage or early-stage biopharmaceutical company, positive study results are material to investors' assessment of pipeline value and development progress, but this disclosure does not fit the standard taxonomy categories (not an earnings release, M\u0026A activity, executive change, or other enumerated event). This is best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:58:11.133502+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4344,"accession_number":"0001193125-26-257430","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"This disclosure reports positive preclinical and early clinical data for AN2-502998, a Chagas disease therapeutic candidate. The 28-day NHP study showed 100% parasite elimination with durable effect and no adverse events, while the Phase 1 FIH study demonstrated good tolerability and human exposures meeting NHP efficacy thresholds. While this represents material clinical progress for a development-stage biotech company, it does not fit neatly into the standard 8-K taxonomy—it is neither an earnings release, executive change, M\u0026A activity, nor a specific adverse event (impairment, litigation, covenant breach, etc.). The data would materially affect investor assessment of the company's pipeline prospects and valuation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:58:11.133502+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4343,"accession_number":"0001193125-26-257430","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"AN2 Therapeutics announced positive clinical trial results for AN2-502998, an oral CPSF3 inhibitor for chronic Chagas disease. For a clinical-stage or early-stage biopharmaceutical company, positive study results are material to investors' assessment of pipeline value and development progress, but this disclosure does not fit the standard taxonomy categories (not an earnings release, M\u0026A activity, executive change, or other enumerated event). This is best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:58:11.133502+00:00","company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","filing_date":"2026-06-04"},{"id":4344,"accession_number":"0001193125-26-257430","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"This disclosure reports positive preclinical and early clinical data for AN2-502998, a Chagas disease therapeutic candidate. The 28-day NHP study showed 100% parasite elimination with durable effect and no adverse events, while the Phase 1 FIH study demonstrated good tolerability and human exposures meeting NHP efficacy thresholds. While this represents material clinical progress for a development-stage biotech company, it does not fit neatly into the standard 8-K taxonomy—it is neither an earnings release, executive change, M\u0026A activity, nor a specific adverse event (impairment, litigation, covenant breach, etc.). The data would materially affect investor assessment of the company's pipeline prospects and valuation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:58:11.133502+00:00","company_name":"AN2 Therapeutics, Inc.","ticker":"ANTX","filing_date":"2026-06-04"}]}